WALLINGFORD — Bristol-Myers Squibb will lay off more than 100 employees at its Research Parkway facility in the coming months as the company prepares to end operations in Wallingford by the end of the year.
The pharmaceutical giant has informed the state it will lay off 107 employees by April 3, according to a worker adjustment and retraining notification (WARN) that Bristol-Myers filed with the Department of Labor this month. Federal law requires employers of 100 or more full-time workers to notify DOL of layoffs in certain circumstances.
This is the largest wave of layoffs at the Wallingford site since Bristol-Myers announced its closing in June 2015, according to information provided by DOL.
Bristol-Myers initially announced in 2015 that it planned to move some jobs in Wallingford to other locations in Connecticut, but later announced it will leave Connecticut entirely by the end of 2018.
Since December 2016, the number of employees at the Wallingford site has gone from about 700 employees to 400 today.
Bristol-Myers plans to “continue operations at the site until December 2018 through a lease-back agreement,” according to company spokeswoman Lisa McCormick Lavery.
Ninety-seven of the 107 layoffs filed with the state earlier this month will become effective April 3, according to the WARN notice. Fifty-three of the positions cut will be clinical managers. The other layoffs include a wide-variety of jobs.
Calare Properties, a Massachusetts real estate firm, announced last week that it purchased Bristol-Myers’ 180-acre property for $5 million. The firm hopes to lease the facility to another bioscience company.